EN DE

Sinopharm Group (1099) Fair Value & Analysis

Healthcare · HK · Market cap HK$49.6B

SG Sinopharm Group 1099 · HK
PriceHK$16.74
Fair ValueHK$58.67
Upside+250.5%
Quality56/100
Watch Sinopharm Group for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Thin margins · 1.2% net margin
Low debt · generates free cash flow
4.27% dividend yield
Ranks above peers (9/13)
Narrow moat 25/100
Evidence: Medium Range HK$44.00 – HK$73.33 Share as image

Fair value as of: Aug 13, 2026

From 24 valuation models · updated today

Share price −1.6% over the past month.

A solid business, screening 250% undervalued on our models.

What matters now

  • The price is below even our cautious bear case (HK$44.00). The market is more pessimistic than our downside scenario.
  • Solid quality (56/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

HK$23.87 HK$12.35 Fair Value HK$58.67 Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$12.35 – HK$23.87 · fair‑value band HK$44.00 – HK$73.33 · the HK$16.74 price screens below the HK$58.67 fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Sinopharm Group (1099) currently trades at HK$16.74, while our model-based Fair Value estimate is HK$58.67, implying the stock looks roughly 250.5% undervalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Sinopharm Group generated revenue of HK$574B at a net margin of 1.2%. Revenue declined 0.6% year over year. It earns a return on equity of 8.1%. Net debt stands at HK$47.0B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$44.00 (bear case) to HK$73.33 (bull case); at HK$16.74, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 10% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at 250%, 1099 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF HK$69.31 HK$106.16 HK$167.90 80
Residual Income HK$22.74 HK$24.62 HK$30.94 76
Rev-Margin DCF HK$66.19 HK$100.68 HK$144.66 74
All 24 models by family
DCF Models
FCF DCF HK$69.54 HK$109.24 HK$177.28 38
Owner Earnings HK$58.57 HK$89.73 HK$143.13 31
5Y Revenue Exit HK$66.19 HK$101.48 HK$149.06 39
5Y EBITDA Exit HK$77.55 HK$124.64 HK$183.37 41
5Y P/E Exit HK$58.57 HK$85.93 HK$116.61 38
10Y Revenue Exit HK$65.31 HK$99.10 HK$150.12 36
10Y EBITDA Exit HK$74.39 HK$115.96 HK$178.54 37
10Y P/E Exit HK$61.86 HK$87.78 HK$123.25 35
Earnings-Based
Graham-Dodd HK$15.59 HK$69.55 HK$95.28 54
Lynch FV HK$18.07 HK$25.82 HK$33.56 50
PEG = 1.0 HK$18.07 HK$25.82 HK$33.56 46
EPV HK$55.41 HK$61.56 HK$66.93 59
Multiples
P/E Multiple HK$37.83 HK$50.44 HK$63.05 63
P/S Multiple HK$29.23 HK$38.98 HK$48.72 58
P/B Multiple HK$29.23 HK$38.98 HK$48.72 55
EV/EBIT HK$84.10 HK$105.94 HK$127.78 53
EV/EBITDA HK$86.97 HK$109.76 HK$132.56 54
EV/Revenue HK$65.34 HK$85.38 HK$105.43 43
Asset-Based
NCAV (Graham) HK$13.46 HK$18.03 HK$26.92 50
Growth DCF
Growth DCF HK$69.31 HK$106.16 HK$167.90 80
Rev-Margin DCF HK$66.19 HK$100.68 HK$144.66 74
Economic Profit
Residual Income HK$22.74 HK$24.62 HK$30.94 76
ROIC Compounder HK$58.81 HK$69.76 HK$82.48 72
Growth Earnings
Growth-Adj P/E HK$30.32 HK$43.31 HK$56.30 68

Widest divergence: Growth DCF (HK$100.68) versus Asset-Based (HK$18.03). Highest evidence: Growth DCF (80).

Notify me when 1099 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) HK$574B
Revenue growth (YoY) -0.6%
Net margin 1.2%
Return on equity 8.1%
Free cash flow HK$12.5B FY2025
P/E ratio 6.0 as of Jul 2, 2026
More key figures
Operating margin 2.2%
EPS (TTM) HK$3.94
Dividend yield 4.3%
EPS growth (YoY) -4.3%
Net debt HK$47.0B FY2025

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 56/100

Of which business quality 56 · Market factors (momentum, volatility) 48

Profitability 41
Margins and returns on capital today
Quality Growth 40
Are margins and returns improving?
Cashflow 58
Earnings quality: real cash, not paper profit
Fin. Strength 47
Balance sheet, leverage, solvency risk
Investment 84
Disciplined investing over empire-building
Low Volatility 93
Calm price path (market factor)
Momentum 31
Price trend over the last 3–12 months (market factor)
52W Momentum 26
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business.

Full company description

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices Distribution segment distributes medical devices, as well as provides installation and maintenance services. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the distribution of laboratory supplies; manufacture and distribution of chemical reagents; and production and sale of pharmaceutical products. The company rents and manages properties; distributes medical instruments and equipment, Chinese herbal medicines, antibiotics, and biological products; and offers information technology, investment, goods and technology import and export, business consulting, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. It also manages medical project investment, consulting, and technology training activities; and manufactures medicines. Sinopharm Group Co. Ltd. was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Sinopharm Group reported revenue of HK$575B in FY2025 versus HK$521B in FY2021, a compound +2.5%/yr. Reported net income was HK$7.2B in FY2025, compounding −2.0%/yr from FY2021.

Growth Quality 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$575B
Latest YoY
−1.6%
Avg. growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.4%
Avg. growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+4.7%
Avg. growth/yr (19Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.3%
Revenue +2.5%/yr
FY21 HK$521B
FY22 HK$552B
FY23 HK$597B
FY24 HK$585B
FY25 HK$575B
Net income −2.0%/yr
FY21 HK$7.8B
FY22 HK$8.5B
FY23 HK$9.1B
FY24 HK$7.0B
FY25 HK$7.2B
Character of growth · EPS growth decomposed (2014-2025) +6.7 % p.a.
Revenue per share +9.3 pp

of which total revenue +11.0 pp · buybacks/dilution −1.7 pp

EBIT margin −3.1 pp
Tax rate −0.5 pp
Residual (interest, one-offs) +1.0 pp

Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).

Watch 1099: get an alert when its fair value changes →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sinopharm Group · Fair Value
HK$58.67 +250%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sinopharm Group Fair Value". https://www.fairvalue-calculator.com/stock/1099

Peer Group

Medical Distribution · 77 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 56 · Above median
Return on equity (TTM) 8% · Above median
Return on assets 3% · Above median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 2% · Below median
Revenue growth -1% · Below median
Dividend yield (TTM) 4.3% · Top 25%
Debt / equity 0.04× · Lower than median

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/E (TTM) 6.0× · Cheaper than 75% of peers
P/B 0.59× · Cheaper than 75% of peers
P/S (TTM) 0.09× · Cheaper than 75% of peers
P/FCF 0.5× · Cheaper than median
PEG 2.31× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 27
FUTURE 0 · sector 17
PAST 32 · sector 22
HEALTH 98 · sector 97
DIVIDEND 85 · sector 52

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $878.73 $819.31 -7%
Cencora, Inc COR $314.17 $211.07 -33%
Cardinal Health, Inc CAH $234.16 $141.77 -39%
Henry Schein, Inc HSIC $90.74 $71.70 -21%
Shanghai Pharmaceuticals Holding 601607 ¥16.56 ¥33.96 +105%
Galenica AG GALE CHF 80.85 CHF 61.79 -24%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.49 ¥28.65 +33%
Jointown Pharmaceutical Group 600998 ¥5.04 ¥9.84 +95%
Asker Healthcare Group ASKER kr 80.00 kr 28.26 -65%
China National Medicines Corporation 600511 ¥27.35 ¥58.22 +113%

Compare Sinopharm Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Sinopharm Group (1099) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of HK$58.67 versus a price of HK$16.74, about +250% (undervalued).
What is the fair value of 1099?
Our model-based fair value for Sinopharm Group is HK$58.67 (as of Aug 13, 2026), built from audited fundamentals. The current price is HK$16.74.
What is the quality score of 1099?
Sinopharm Group has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Sinopharm Group (1099)?
Sinopharm Group reported trailing-twelve-month revenue of about HK$574B (latest available figure, as of Aug 13, 2026).
What is the net profit margin of 1099?
The net profit margin of Sinopharm Group is about 1.2%, meaning it keeps roughly 1.2% of revenue as net income. Based on the latest reported figures.
Does Sinopharm Group pay a dividend?
Sinopharm Group currently shows a dividend yield of about 4.27% relative to its recent price (as of Aug 13, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Sinopharm Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.